ImmuCell (NASDAQ:ICCC) CEO Boekhorst Paul Francis Oliv Te Purchases 8,000 Shares of Stock

ImmuCell Corporation (NASDAQ:ICCC) CEO Boekhorst Paul Francis Oliv Te acquired 8,000 shares of ImmuCell stock in a transaction on Thursday, June 18th. The shares were bought at an average cost of $9.49 per share, for a total transaction of $75,920.00. Following the completion of the purchase, the chief executive officer directly owned 17,785 shares of the company’s stock, valued at $168,779.65. The trade was a 81.76% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ImmuCell Price Performance

NASDAQ ICCC opened at $9.49 on Monday. The company has a fifty day moving average of $8.97 and a two-hundred day moving average of $7.22. The firm has a market capitalization of $85.88 million, a price-to-earnings ratio of -158.14 and a beta of 0.55. The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24. ImmuCell Corporation has a 52 week low of $4.52 and a 52 week high of $10.75.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Thursday, May 14th. The biotechnology company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.05 by $0.16. The company had revenue of $10.36 million for the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ICCC. Militia Capital Management LLC acquired a new position in shares of ImmuCell during the first quarter valued at about $114,000. Steadtrust LLC purchased a new position in shares of ImmuCell during the 3rd quarter valued at about $198,000. Mesirow Financial Investment Management Inc. lifted its holdings in ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after acquiring an additional 24,303 shares during the period. Dimensional Fund Advisors LP increased its holdings in ImmuCell by 3.2% in the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 1,749 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after purchasing an additional 2,907 shares during the period. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings cut ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a report on Monday, April 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.